Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 214

Sort by

Sort Order Select

Journal Articles

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Divaya Bhutani, Shami Chakrabarti, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Markus Mapara, Abhinav Deol, Joseph Uberti, Ran Reshef

Blood (2025) 146 (Supplement 1): 4062.

https://doi.org/10.1182/blood-2025-4062

Published: 2025

Journal Articles

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Josefine Krüger, Shirong Li, Guifen Liu, Yuen Lam Dora Ng, Michael Hughes, Rajshekhar Chakraborty, Divaya Bhutani, Jan Krönke, Suzanne Lentzsch, Jing Fu

Blood (2025) 146 (Supplement 1): 2150.

https://doi.org/10.1182/blood-2025-2150

Published: 2025

Journal Articles

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

Divaya Bhutani, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Samuel Pan, Shayan Shirazayan, Sherley Mejia, Naomi Sender, Elizabeth Shelton, Meghan Sise

Blood (2025) 146 (Supplement 1): 579.

https://doi.org/10.1182/blood-2025-579

Published: 2025

Journal Articles

Development of a high-affinity antibody specific to the predominant λ light chain amyloid subtype for AL amyloidosis immunotherapy

Michael Hughes, Gavreel Kalantarov, Jing Fu, Miroslav Sekulic, Glen Markowitz, Josefine Krüger, Guifen Liu, HuiHui Ma, Markus Mapara, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 576.

https://doi.org/10.1182/blood-2025-576

Published: 2025

Journal Articles

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, Raja Prince-Eladnani, Ajay Nooka, David Vesole, Barry Paul, Parameswaran Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin Van Vliet, David Siegel, Saad Usmani, Frits van Rhee

Blood (2025) 146 (Supplement 1): 2220.

https://doi.org/10.1182/blood-2025-2220

Published: 2025

Journal Articles

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Samuel Rubinstein, Yusha Liu, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Jing Christine Ye, Divaya Bhutani

Blood (2025) 146 (Supplement 1): 3973.

https://doi.org/10.1182/blood-2025-3973

Published: 2025

Journal Articles

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Simon Zhen, Divaya Bhutani, Mathew Maurer, Karan Wats, Yevgeniy Brailovsky, Michael Hughes, Jai Radhakrishnan, Markus Mapara, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5740.

https://doi.org/10.1182/blood-2025-5740

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Michael Hughes, Yiran Peng, Shikun Wang, Andrew Laine, Jai Radhakrishnan, Metodi Balev, Divaya Bhutani, Markus Mapara, Andrew Eisenberger, Suzanne Lentzsch, Rajshekhar Chakraborty

Blood (2025) 146 (Supplement 1): 5756.

https://doi.org/10.1182/blood-2025-5756

Published: 2025

Journal Articles

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis

Jing Fu, Huihui Ma, Gavreel Kalantarov, Michael Hughes, Guifen Liu, Markus Mapara, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 3919.

https://doi.org/10.1182/blood-2025-3919

Published: 2025

Journal Articles

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Prashant Kapoor, Shikun Wang, Divaya Bhutani, Susan Bal, Keith Stockerl-Goldstein, Sherin Selvan, Othman Akhtar, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 694.

https://doi.org/10.1182/blood-2025-694

Published: 2025

Journal Articles

Long-term follow-up of venetoclax therapy in AL amyloidosis

Divaya Bhutani, Rajshekhar Chakraborty, Suzanne Lentzsch, Michael Hughes, Michaela Liedtke, Jeffrey Zonder, Mansen Yu, Anita D'Souza

Blood (2025) 146 (Supplement 1): 7497.

https://doi.org/10.1182/blood-2025-7497

Published: 2025

Journal Articles

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Rajshekhar Chakraborty, Anita D'Souza, Omar Siddiqi, Shikun Wang, Margaret Doyle, Sanjay Vara, Benjamin Schroeder, Jordan Schecter, Catherine Higgins, Renee Smith, Vaishali Sanchorawala, Suzanne Lentzsch

Blood (2025) 146 (Supplement 1): 2197.

https://doi.org/10.1182/blood-2025-2197

Published: 2025

Journal Articles

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

Divaya Bhutani, Samuel Rubinstein, Rajshekhar Chakraborty, Michael Hughes, Suzanne Lentzsch, Lu Dai, Micah Richardson, J Christine Ye

Blood (2025) 146 (Supplement 1): 2194.

https://doi.org/10.1182/blood-2025-2194

Published: 2025

Journal Articles

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)

Suzanne Lentzsch, Heather Landau, Vishal Kukreti, Sandra Mazzoni, Richa Manwani, Amit Bhattacharyya, Akhilesh Chamediya, Ashutosh Wechalekar

Blood (2025) 146 (Supplement 1): 8236.

https://doi.org/10.1182/blood-2025-8236

Published: 2025

Journal Articles

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Abdul-Hamid Bazarbachi, HuiHui Ma, Simon Zhen, Miriam Klahr, Diane M. George, Christian Gordillo, Samuel Pan, Amer Assal, Andrew Eisenberger, David Diuguid, Ran Reshef, Suzanne Lentzsch, Divaya Bhutani, Rajshekhar Chakraborty, Monica Bhatia, Markus Mapara

Blood (2025) 146 (Supplement 1): 4255.

https://doi.org/10.1182/blood-2025-4255

Published: 2025

Journal Articles

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Pedro Vianna, Rajshekhar Chakraborty, Shahrier Hossain, Divaya Bhutani, Shannon Miller, Annemarie Rossi, Sarah A. M. Cuddy, Rodney H. Falk, Suzanne Lentzsch, Jacob P. Laubach, Giada Bianchi

Blood (2025) 146 (16): 1929–1935.

https://doi.org/10.1182/blood.2025028383

Published: 2025

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A. Gertz, Angela Dispenzieri, Shaji Kumar, Anita D’Souza, Anannya Patwari, Andrew Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan O. Schönland, Suzanne Lentzsch, Eli Muchtar

Blood (2024) 144 (25): 2613–2624.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Blood (2024) 144 (Supplement 1): 3781.

https://doi.org/10.1182/blood-2024-203609

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Effect of isatuximab use in combination with autologous stem cell transplant on mobilized stem cell product and post-transplant immune recovery - Results of a randomized prospective Phase 2 trial

Deciphering the IKZF1 and MAP4K2 protein interactome in RASMut multiple myeloma reveals a novel regulatory pathway of IKZF1

Isatuximab for the treatment of monoclonal gammopathy of renal significance (MGRS): Results from a prospective multicenter Phase 2 trial

Development of a high-affinity antibody specific to the predominant λ light chain amyloid subtype for AL amyloidosis immunotherapy

Prospective real-world evaluation of SKY92 for risk stratification in multiple myeloma: Comparison with updated ims/IMWG criteria in the prommis study

Determinants of renal survival in patients treated for monoclonal gammopathy of renal significance

Outcomes of patients with mayo stage IIIb systemic AL amyloidosis treated with daratumumab-based frontline therapy

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Machine learning uncovers prognostically distinct myeloma cast nephropathy phenotypes not captured by standard risk stratification systems

Harnessing phagocytes for amyloid clearance: Development of a novel bispecific phagocyte engager (LC Fibril x CD64) for AL amyloidosis

An open-label multicenter Phase 1/2 trial of venetoclax-dexamethasone in Relapsed/Refractory t(11;14)-positive systemic AL amyloidosis

Long-term follow-up of venetoclax therapy in AL amyloidosis

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Better renal response with daratumumab in patients with monoclonal immunoglobulin deposition disease

ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)

Computational dissection of immune reconstitution across diverse conditioning regimens in adults with sickle cell disease undergoing allogeneic stem cell transplantation

Safety and efficacy of elranatamab in patients with relapsed and/or refractory immunoglobulin light-chain amyloidosis

Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Efficacy and Safety of Teclistamab in Relapsed Refractory Multiple Myeloma: Long-Term Follow-up from a Real World Multi-Institutional Cohort

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only